The Central Drugs Standard Control Organisation (CDSCO) has cancelled the registration certificate granted to a cosmetic product after it was found to be marketed for treatment of medical conditions.
The product, QR 678-Neo, was being promoted for the treatment of androgenetic alopecia and hair loss following chemotherapy. However, such claims fall under the definition of a drug as per the Drugs and Cosmetics Act, 1940.
According to officials, the product had been registered as a cosmetic but was being advertised and promoted with therapeutic claims, which is not permissible under the Cosmetic Rules, 2020. The regulator observed that products intended for treatment or prevention of disease cannot be classified as cosmetics.
The decision followed a review of promotional material and claims associated with the product. CDSCO stated that any product making therapeutic claims requires appropriate approval as a drug and must comply with the regulatory framework applicable to pharmaceuticals.
Authorities reiterated that cosmetics are meant for cleansing, beautifying, promoting attractiveness or altering appearance, and not for treating or preventing disease conditions.
The registration certificate has been revoked, and necessary action has been initiated as per applicable provisions.